Principal Financial Group Inc Nektar Therapeutics Transaction History

Principal Financial Group Inc

$1.66 Trillion
Q3 2024

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	SELL	$1.11 - $1.48 $5,605 - $7,474	-5,050 Reduced 28.85%	12,455 $16,000
Q2 2024 Jul 29, 2024	SELL	$0.9 - $1.83 $29,655 - $60,300	-32,951 Reduced 65.31%	17,505 $21,000
Q1 2024 Apr 29, 2024	SELL	$0.49 - $0.96 $762 - $1,493	-1,556 Reduced 2.99%	50,456 $46,000
Q4 2023 Feb 07, 2024	SELL	$0.42 - $0.57 $2,428 - $3,295	-5,781 Reduced 10.0%	52,012 $29,000
Q3 2023 Nov 02, 2023	BUY	$0.51 - $1.05 $2,427 - $4,996	4,759 Added 8.97%	57,793 $34,000
Q2 2023 Aug 07, 2023	SELL	$0.53 - $1.03 $587,184 - $1.14 Million	-1,107,896 Reduced 95.43%	53,034 $30,000
Q1 2023 May 09, 2023	SELL	$0.64 - $3.15 $10,794 - $53,131	-16,867 Reduced 1.43%	1,160,930 $812,000
Q4 2022 Feb 09, 2023	BUY	$2.03 - $4.28 $6,520 - $13,747	3,212 Added 0.27%	1,177,797 $2.66 Million
Q3 2022 Nov 09, 2022	BUY	$3.04 - $5.14 $16,233 - $27,447	5,340 Added 0.46%	1,174,585 $3.76 Million
Q2 2022 Aug 10, 2022	SELL	$3.17 - $6.17 $273,748 - $532,816	-86,356 Reduced 6.88%	1,169,245 $4.44 Million
Q1 2022 May 09, 2022	SELL	$4.16 - $13.72 $25,783 - $85,036	-6,198 Reduced 0.49%	1,255,601 $6.77 Million
Q4 2021 Feb 09, 2022	BUY	$10.83 - $18.41 $6.39 Million - $10.9 Million	589,861 Added 87.79%	1,261,799 $17 Million
Q3 2021 Nov 09, 2021	SELL	$13.07 - $18.84 $48,620 - $70,084	-3,720 Reduced 0.55%	671,938 $12.1 Million
Q2 2021 Aug 10, 2021	BUY	$16.52 - $20.4 $163,581 - $202,000	9,902 Added 1.49%	675,658 $11.6 Million
Q1 2021 May 10, 2021	BUY	$16.56 - $25.46 $1.62 Million - $2.49 Million	97,703 Added 17.2%	665,756 $13.3 Million
Q4 2020 Feb 08, 2021	BUY	$15.77 - $19.03 $8,988 - $10,847	570 Added 0.1%	568,053 $9.66 Million
Q3 2020 Nov 06, 2020	SELL	$16.59 - $24.79 $279,027 - $416,943	-16,819 Reduced 2.88%	567,483 $9.41 Million
Q2 2020 Aug 05, 2020	BUY	$16.86 - $23.44 $461,896 - $642,162	27,396 Added 4.92%	584,302 $13.5 Million
Q1 2020 May 12, 2020	SELL	$14.47 - $27.96 $3.12 Million - $6.03 Million	-215,824 Reduced 27.93%	556,906 $9.94 Million
Q4 2019 Feb 05, 2020	BUY	$15.87 - $23.12 $7.94 Million - $11.6 Million	500,466 Added 183.82%	772,730 $16.7 Million
Q3 2019 Nov 13, 2019	SELL	$16.91 - $36.27 $118,674 - $254,542	-7,018 Reduced 2.51%	272,264 $4.96 Million
Q2 2019 Aug 12, 2019	SELL	$31.0 - $36.3 $329,530 - $385,868	-10,630 Reduced 3.67%	279,282 $9.94 Million
Q1 2019 May 10, 2019	BUY	$31.58 - $46.35 $53,212 - $78,099	1,685 Added 0.58%	289,912 $9.74 Million
Q4 2018 Feb 14, 2019	BUY	$30.43 - $56.65 $80,243 - $149,386	2,637 Added 0.92%	288,227 $9.47 Million
Q3 2018 Nov 14, 2018	BUY	$46.46 - $68.49 $1.83 Million - $2.7 Million	39,389 Added 16.0%	285,590 $17.4 Million
Q2 2018 Aug 13, 2018	SELL	$46.25 - $104.45 $5.57 Million - $12.6 Million	-120,363 Reduced 32.84%	246,201 $0
Q1 2018 May 14, 2018	SELL	$57.4 - $108.44 $59.7 Million - $113 Million	-1,039,693 Reduced 73.93%	366,564 $39 Million
Q4 2017 Feb 13, 2018	SELL	$23.02 - $60.5 $1.19 Million - $3.13 Million	-51,750 Reduced 3.55%	1,406,257 $84 Million
Q3 2017 Nov 02, 2017	BUY	$17.79 - $24.0 $25.9 Million - $35 Million	1,458,007	1,458,007 $35 Million

Others Institutions Holding NKTR

# of Institutions

145

Shares Held

139M

Call Options Held

32.6K

Put Options Held

14.1K

Deep Track Capital, LP Greenwich, CT

15.9M
Shares

$14.5 Million
0.76% of portfolio
Black Rock Inc. New York, NY

15.2M
Shares

$13.8 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

13.1M
Shares

$11.9 Million
0.0% of portfolio
Eventide Asset Management, LLC Boston, MA

9.4M
Shares

$8.55 Million
0.22% of portfolio
Samlyn Capital, LLC New York, NY

9.2M
Shares

$8.37 Million
0.19% of portfolio

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $171M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account